Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CREBBP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CREBBP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CREBBP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CREBBP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CREBBP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CREBBP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CREBBP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CREBBP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CREBBP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CREBBP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003210315 | Skin | SCCIS | positive regulation of response to external stimulus | 51/919 | 427/18723 | 3.99e-09 | 1.76e-06 | 51 |
GO:0009314110 | Skin | SCCIS | response to radiation | 50/919 | 456/18723 | 9.08e-08 | 1.27e-05 | 50 |
GO:0048511110 | Skin | SCCIS | rhythmic process | 35/919 | 298/18723 | 1.63e-06 | 9.13e-05 | 35 |
GO:0071214110 | Skin | SCCIS | cellular response to abiotic stimulus | 36/919 | 331/18723 | 6.89e-06 | 2.67e-04 | 36 |
GO:0104004110 | Skin | SCCIS | cellular response to environmental stimulus | 36/919 | 331/18723 | 6.89e-06 | 2.67e-04 | 36 |
GO:007147817 | Skin | SCCIS | cellular response to radiation | 23/919 | 186/18723 | 4.31e-05 | 1.08e-03 | 23 |
GO:000283113 | Skin | SCCIS | regulation of response to biotic stimulus | 32/919 | 327/18723 | 1.67e-04 | 3.31e-03 | 32 |
GO:000276414 | Skin | SCCIS | immune response-regulating signaling pathway | 41/919 | 468/18723 | 2.48e-04 | 4.52e-03 | 41 |
GO:000225314 | Skin | SCCIS | activation of immune response | 33/919 | 375/18723 | 8.93e-04 | 1.15e-02 | 33 |
GO:0001666112 | Skin | SCCIS | response to hypoxia | 28/919 | 307/18723 | 1.25e-03 | 1.46e-02 | 28 |
GO:003134913 | Skin | SCCIS | positive regulation of defense response | 26/919 | 278/18723 | 1.28e-03 | 1.49e-02 | 26 |
GO:000941612 | Skin | SCCIS | response to light stimulus | 28/919 | 320/18723 | 2.29e-03 | 2.30e-02 | 28 |
GO:0036293112 | Skin | SCCIS | response to decreased oxygen levels | 28/919 | 322/18723 | 2.51e-03 | 2.43e-02 | 28 |
GO:001657016 | Skin | SCCIS | histone modification | 37/919 | 463/18723 | 2.53e-03 | 2.44e-02 | 37 |
GO:0031647112 | Skin | SCCIS | regulation of protein stability | 26/919 | 298/18723 | 3.35e-03 | 3.00e-02 | 26 |
GO:0070482112 | Skin | SCCIS | response to oxygen levels | 29/919 | 347/18723 | 3.77e-03 | 3.27e-02 | 29 |
GO:00028333 | Skin | SCCIS | positive regulation of response to biotic stimulus | 17/919 | 168/18723 | 3.77e-03 | 3.27e-02 | 17 |
GO:007156017 | Skin | SCCIS | cellular response to transforming growth factor beta stimulus | 22/919 | 250/18723 | 6.00e-03 | 4.61e-02 | 22 |
GO:003164729 | Skin | cSCC | regulation of protein stability | 144/4864 | 298/18723 | 6.51e-17 | 6.80e-15 | 144 |
GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CREBBP | SNV | Missense_Mutation | novel | c.2368N>A | p.Gln790Lys | p.Q790K | Q92793 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CREBBP | SNV | Missense_Mutation | | c.2114A>G | p.Asn705Ser | p.N705S | Q92793 | protein_coding | deleterious_low_confidence(0.04) | benign(0.351) | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.3860N>A | p.Gly1287Asp | p.G1287D | Q92793 | protein_coding | deleterious(0.01) | benign(0.077) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | novel | c.4175G>A | p.Arg1392Gln | p.R1392Q | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.3505C>T | p.Arg1169Cys | p.R1169C | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.6803N>C | p.Met2268Thr | p.M2268T | Q92793 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.599) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CREBBP | SNV | Missense_Mutation | | c.4349N>G | p.Tyr1450Cys | p.Y1450C | Q92793 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CREBBP | SNV | Missense_Mutation | | c.4563N>A | p.Asp1521Glu | p.D1521E | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CREBBP | SNV | Missense_Mutation | novel | c.4778N>A | p.Thr1593Asn | p.T1593N | Q92793 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | | c.6303N>G | p.Ile2101Met | p.I2101M | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | (-)-ROLIPRAM | (-)-ROLIPRAM | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | ETAZOLATE | ETAZOLATE | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | TRIAZOLAM | TRIAZOLAM | 22137933 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DNDI1417457 | CHEMBL1530911 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | ESTAZOLAM | ESTAZOLAM | 22137933 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLMALONATE | CHEMBL1797712 | 21292492 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | PAPAVERINE | PAPAVERINE | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | C 82 | | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | | PRI-724 | PRI-724 | |